Senseonics has unveiled a significant collaboration with Rimidi aimed at forging a robust remote patient monitoring program. Rimidi specializes in crafting clinical management platforms to streamline workflows, elevate patient care experiences, and achieve goals in chronic disease management. Together, the two entities aspire to pioneer the Eversense remote patient monitoring (RPM) initiative, tailored for healthcare providers.
At the heart of Senseonics' endeavors lies the Eversense long-term, implantable continuous glucose monitor (CGM). Setting itself apart as the lengthiest enduring CGM on the market, Eversense boasts a six-month wear duration and requires just a single insertion. Its precision in crucial low glucose ranges and minimal incidence of compression lows render it a standout choice. Moreover, the system incorporates alert detection capabilities to facilitate real-time corrections with utmost accuracy.
Just last week, the FDA bestowed upon Eversense the integrated CGM designation, a pivotal milestone. This designation empowers seamless integration with insulin pumps, forming an integral component of automated insulin delivery systems.
Click here to read the original news story.